Doxorubicin Liposomal

Form: Liposomal Injection (

Strength: 20 mg/10 mL (2 mg/mL), 50 mg/25 mL (2 mg/mL)

Reference Brands: Doxil® , Caelyx® (EU & US)

Category: Oncology Cancer Care

Doxorubicin Liposomal, marketed as Doxil® (US) and Caelyx® (EU), is a chemotherapy agent used to treat breast cancer, ovarian cancer, Kaposi’s sarcoma, and multiple myeloma. Its liposomal formulation encapsulates the doxorubicin drug, allowing for more targeted delivery and reduced systemic toxicity compared to conventional doxorubicin. Available in 20 mg/10 mL and 50 mg/25 mL concentrations, it is supplied in single-use vials for oncology treatment. Sourced from GMP-compliant manufacturers, Doxorubicin Liposomal offers effective treatment for cancer patients while minimizing side effects, making it a trusted choice for healthcare providers in US and EU markets.